🇺🇸 FDA
Pipeline program

Fasiglifam

TAK-875_203

Phase 3 small_molecule terminated

Quick answer

Fasiglifam for Type 2 Diabetes Mellitus is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 2 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Type 2 Diabetes Mellitus
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials